MA39155A1 - Composition de solution d'aérosol stable, mise sous pression, de combinaison de bromure de glycopyrronium et de formotérol - Google Patents
Composition de solution d'aérosol stable, mise sous pression, de combinaison de bromure de glycopyrronium et de formotérolInfo
- Publication number
- MA39155A1 MA39155A1 MA39155A MA39155A MA39155A1 MA 39155 A1 MA39155 A1 MA 39155A1 MA 39155 A MA39155 A MA 39155A MA 39155 A MA39155 A MA 39155A MA 39155 A1 MA39155 A1 MA 39155A1
- Authority
- MA
- Morocco
- Prior art keywords
- formoterol
- combination
- glycopyrronium bromide
- aerosol solution
- hydroxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
- A61M15/007—Mechanical counters
- A61M15/0071—Mechanical counters having a display or indicator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0086—Inhalation chambers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/22—Valves or arrangement of valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/22—Valves or arrangement of valves
- A61M2039/226—Spindles or actuating means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
- A61M2205/0238—General characteristics of the apparatus characterised by a particular materials the material being a coating or protective layer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
- Filling Or Discharging Of Gas Storage Vessels (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
L'invention concerne une composition de solution d'aérosol, conçue pour être utilisée avec un aérosol-doseur mis sous pression, comportant du bromure de glycopyrronium et du formotérol, ou un sel de ceux-ci ou un solvate dudit sel, facultativement en combinaison avec un ou plusieurs principes actifs supplémentaires, stabilisée par une quantité choisie d'un acide minéral, la quantité de produit de dégradation n-(3-bromo)-[2-hydroxy-5-[l-hydroxy-2-[l-(4- méthoxyphényl) propan-2-ylamino]éthyl] phényl] formamide étant inférieure à la limite de quantification, lorsqu'elle est stockée dans des conditions accélérées à 25 °c et à une humidité relative (rh) de 60 % pendant 6 mois dans une boîte recouverte intérieurement par une résine comportant un polymère d'éthylène-propylène fluoré (fep). Le ou les principes actifs facultatifs peuvent être un corticostéroïde d'inhalation choisi parmi le dipropionate de béclométasone, le budésonide ou son épimère 22r, le ciclésonide, le flunisolide, le propionate de fluticasone, le furoate de fluticasone, le furoate de mométasone, etc.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13199784 | 2013-12-30 | ||
| PCT/EP2014/079259 WO2015101576A1 (fr) | 2013-12-30 | 2014-12-23 | Composition de solution d'aérosol stable, mise sous pression, de combinaison de bromure de glycopyrronium et de formotérol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA39155A1 true MA39155A1 (fr) | 2017-04-28 |
Family
ID=49886777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39155A MA39155A1 (fr) | 2013-12-30 | 2016-06-28 | Composition de solution d'aérosol stable, mise sous pression, de combinaison de bromure de glycopyrronium et de formotérol |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US10596113B2 (fr) |
| EP (3) | EP3566694A1 (fr) |
| JP (2) | JP6563950B2 (fr) |
| KR (2) | KR101861117B1 (fr) |
| CN (2) | CN111150728B (fr) |
| AR (2) | AR098982A1 (fr) |
| AU (1) | AU2014375301C1 (fr) |
| BR (1) | BR112016014583B1 (fr) |
| CA (1) | CA2935305C (fr) |
| CL (1) | CL2016001653A1 (fr) |
| CY (1) | CY1120668T1 (fr) |
| DK (1) | DK3089735T3 (fr) |
| EA (1) | EA033227B1 (fr) |
| ES (1) | ES2687345T3 (fr) |
| GE (1) | GEP20186855B (fr) |
| HR (1) | HRP20181551T1 (fr) |
| HU (1) | HUE039513T2 (fr) |
| IL (1) | IL246498B (fr) |
| LT (1) | LT3089735T (fr) |
| MA (1) | MA39155A1 (fr) |
| MX (1) | MX368835B (fr) |
| MY (1) | MY182861A (fr) |
| PE (1) | PE20160997A1 (fr) |
| PH (1) | PH12016501268B1 (fr) |
| PL (1) | PL3089735T3 (fr) |
| PT (1) | PT3089735T (fr) |
| RS (1) | RS57687B1 (fr) |
| SA (1) | SA516371427B1 (fr) |
| SG (1) | SG11201605311UA (fr) |
| SI (1) | SI3089735T1 (fr) |
| TN (1) | TN2016000261A1 (fr) |
| TW (1) | TWI660747B (fr) |
| UA (1) | UA117845C2 (fr) |
| WO (1) | WO2015101576A1 (fr) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012015334A2 (pt) * | 2009-12-23 | 2016-03-15 | Chiesi Farma Spa | terapia combinada para doença pulmonar obstrutiva crônica |
| MX340264B (es) | 2009-12-23 | 2016-07-04 | Chiesi Farm Spa | Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica. |
| PE20160853A1 (es) | 2009-12-23 | 2016-09-14 | Chiesi Farm Spa | Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) |
| HRP20180944T1 (hr) * | 2013-12-30 | 2018-08-10 | Chiesi Farmaceutici S.P.A. | Stabilan pripravak stlačene aerosolne otopine kombinacije glikopironijeva bromida i formoterola |
| BR112016014583B1 (pt) * | 2013-12-30 | 2022-12-20 | Chiesi Farmaceutici S.P.A | Composição de solução farmacêutica em aerossol, inalador pressurizado de dose calibrada e uso da dita composição |
| GB2545025A (en) * | 2015-12-04 | 2017-06-07 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
| EP3701940B1 (fr) | 2015-12-04 | 2025-11-12 | Mexichem Fluor S.A. de C.V. | Composition pharmaceutique |
| US10098837B2 (en) * | 2016-07-28 | 2018-10-16 | Chiesi Farmaceutici S.P.A. | Combination therapy for COPD |
| CN114515284A (zh) | 2016-09-19 | 2022-05-20 | 墨西哥氟石股份公司 | 药物组合物 |
| CN107233311B (zh) * | 2017-06-27 | 2020-12-04 | 长风药业股份有限公司 | 一种以阿福特罗和格隆溴铵为活性成分的雾化剂及其制备方法 |
| EP3860580A4 (fr) * | 2018-10-01 | 2022-07-20 | Kindeva Drug Delivery L.P. | Formulation et cartouches d'aérosol, inhalateurs et analogues contenant la formulation |
| WO2020084549A1 (fr) * | 2018-10-25 | 2020-04-30 | Glenmark Specialty S.A. | Composition de nébulisation comprenant du glycopyrrolate et du formotérol |
| EP3996672A1 (fr) * | 2019-07-12 | 2022-05-18 | Kindeva Drug Delivery L.P. | Formulation d'aérosol, cartouche et inhalateur contenant la formulation, et procédé d'utilisation |
| US12616654B2 (en) | 2019-12-02 | 2026-05-05 | Chiesi Farmaceutici S.P.A. | Stainless steel can for pressurised metered dose inhalers |
| KR20220133193A (ko) | 2020-01-28 | 2022-10-04 | 키에시 파르마슈티시 엣스. 피. 에이. | 완충된 약제학적 제제를 포함하는 가압 정량 흡입기 |
| WO2021165348A1 (fr) * | 2020-02-20 | 2021-08-26 | Chiesi Farmaceutici S.P.A. | Inhalateurs doseurs sous pression comprenant une formulation pharmaceutique tamponnée |
| AU2021314977B2 (en) * | 2020-07-31 | 2025-03-13 | Chemo Research, S.L. | Combination therapy for inhalation administration |
| CN112051346A (zh) * | 2020-09-24 | 2020-12-08 | 珠海瑞思普利生物制药有限公司 | 一种同时测定茚达特罗和格隆溴铵含量的hplc方法 |
| EP4225267A1 (fr) * | 2020-10-09 | 2023-08-16 | Chiesi Farmaceutici S.p.A. | Formulation pharmaceutique pour inhalateur doseur pressurisé |
| EP4398880A1 (fr) * | 2021-09-08 | 2024-07-17 | Kindeva Drug Delivery L.P. | Inhalateurs doseurs et compositions de suspension |
| US20250058063A1 (en) * | 2021-12-21 | 2025-02-20 | Chiesi Farmaceutici S.P.A. | Dry powder formulations filled in an inhaler with improved resistance to humidity |
| CN116338014A (zh) * | 2021-12-23 | 2023-06-27 | 上海医药工业研究院有限公司 | 一种吸入用药物组合物的组分分离检测方法 |
| WO2023227783A1 (fr) | 2022-05-27 | 2023-11-30 | Chiesi Farmaceutici S.P.A. | Formulation pharmaceutique pour aérosol-doseur sous pression |
| WO2023227781A1 (fr) | 2022-05-27 | 2023-11-30 | Chiesi Farmaceutici S.P.A. | Formulation pharmaceutique pour aérosol-doseur sous pression |
| US20250312274A1 (en) | 2022-05-27 | 2025-10-09 | Chiesi Farmaceutici S.P.A. | A pharmaceutical formulation for pressurised metered dose inhaler |
| CN117679423A (zh) | 2022-09-05 | 2024-03-12 | 立生医药(苏州)有限公司 | 预防或治疗呼吸系统疾病的吸入用药物组合物 |
| TW202600144A (zh) * | 2024-02-23 | 2026-01-01 | 瑞典商阿斯特捷利康公司 | Copd之三重組合療法 |
| WO2026006658A1 (fr) | 2024-06-27 | 2026-01-02 | Lupin Inc. | Compositions pharmaceutiques stables pour inhalateurs doseurs sous pression |
| GR1011131B (el) * | 2025-05-15 | 2026-02-06 | Elpen Ανωνυμος Εταιρεια Φαρμακευτικη Βιομηχανια, | Φαρμακευτικο διαλυμα βεκλομεθαζονης και φορμοτερολης για εισπνοη σε περιεκτη υπο πιεση με τροποιημενη εσωτερικη επιφανεια |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
| EP1102579B1 (fr) | 1998-08-04 | 2003-03-19 | Jago Research Ag | Formulations d'aerosol a usage medical |
| US20060171899A1 (en) * | 1998-12-10 | 2006-08-03 | Akwete Adjei | Water-stabilized aerosol formulation system and method of making |
| IT1317720B1 (it) | 2000-01-07 | 2003-07-15 | Chiesi Farma Spa | Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani. |
| GB0008660D0 (en) | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| JP5392880B2 (ja) | 2000-05-22 | 2014-01-22 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | 加圧式定量吸入器のための安定な製薬学的溶液製剤 |
| US20060257324A1 (en) | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
| US6750210B2 (en) * | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
| EP1241113A1 (fr) * | 2001-03-12 | 2002-09-18 | CHIESI FARMACEUTICI S.p.A. | Inhalateur avec des moyens pour améliorer la stabilité chimique des solutions d'aerosol médicinales qu'il contient |
| EP1321159A1 (fr) | 2001-12-21 | 2003-06-25 | CHIESI FARMACEUTICI S.p.A. | Dispositif d'actionnement pour inhalateur doseur pressurisé avec orifices percés par laser |
| US20040126325A1 (en) * | 2002-03-12 | 2004-07-01 | David Lewis | Medicinal aerosol solution formulation products with improved chemical stability |
| DK1718336T3 (da) | 2004-02-06 | 2008-10-20 | Meda Pharma Gmbh & Co Kg | Ny kombination af anticholinergikum og beta-mimetika til behandling af luftvejssygdomme |
| AU2005210085B2 (en) | 2004-02-06 | 2010-06-24 | Meda Pharma Gmbh & Co. Kg | The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and COPD |
| CN100457087C (zh) * | 2004-02-27 | 2009-02-04 | 奇斯药制品公司 | 用于加压计量吸入器的稳定的药用溶液制剂 |
| GB0410399D0 (en) | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
| EA200602112A1 (ru) * | 2004-05-13 | 2007-04-27 | Кьези Фармачеутичи С. П. А. | Изделие для медицинского аэрозоля |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| WO2006105401A2 (fr) | 2005-03-30 | 2006-10-05 | Schering Corporation | Medicaments et procedes de combinaison d'un anticholinergique, un corticosteroide, et un agoniste beta a action prolongee |
| GB0523653D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523655D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523654D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523656D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| EP2201934A1 (fr) * | 2008-12-23 | 2010-06-30 | CHIESI FARMACEUTICI S.p.A. | Produits de formule d'aérosol de tiotropium avec stabilité chimique améliorée |
| WO2010144628A2 (fr) * | 2009-06-09 | 2010-12-16 | Elevation Pharmaceuticals, Inc. | Traitement d'une maladie pulmonaire obstructive chronique par administration de bêta 2 agoniste nébulisé ou d'une combinaison de bêta 2 agoniste nébulisé et d'anticholinergique |
| PE20160853A1 (es) | 2009-12-23 | 2016-09-14 | Chiesi Farm Spa | Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) |
| MX340264B (es) | 2009-12-23 | 2016-07-04 | Chiesi Farm Spa | Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica. |
| KR20120106753A (ko) | 2009-12-23 | 2012-09-26 | 키에시 파르마슈티시 엣스. 피. 에이. | Ｃｏｐｄ용 에어로졸 제제 |
| BR112012015334A2 (pt) * | 2009-12-23 | 2016-03-15 | Chiesi Farma Spa | terapia combinada para doença pulmonar obstrutiva crônica |
| CN103079618B (zh) | 2010-09-06 | 2015-12-02 | 奇斯药制品公司 | 定量吸入器致动器、定量吸入器 |
| KR20140032404A (ko) * | 2011-05-17 | 2014-03-14 | 펄 테라퓨틱스 인코포레이티드 | ２ 개 이상의 활성제의 호흡기 전달을 위한 조성물, 방법 ＆ 시스템 |
| CN104582771B (zh) | 2012-08-29 | 2018-09-04 | 奇斯药制品公司 | 气溶胶吸入装置 |
| HRP20180944T1 (hr) * | 2013-12-30 | 2018-08-10 | Chiesi Farmaceutici S.P.A. | Stabilan pripravak stlačene aerosolne otopine kombinacije glikopironijeva bromida i formoterola |
| BR112016014583B1 (pt) * | 2013-12-30 | 2022-12-20 | Chiesi Farmaceutici S.P.A | Composição de solução farmacêutica em aerossol, inalador pressurizado de dose calibrada e uso da dita composição |
-
2014
- 2014-12-23 BR BR112016014583-6A patent/BR112016014583B1/pt active IP Right Grant
- 2014-12-23 CA CA2935305A patent/CA2935305C/fr active Active
- 2014-12-23 TN TN2016000261A patent/TN2016000261A1/en unknown
- 2014-12-23 RS RS20181112A patent/RS57687B1/sr unknown
- 2014-12-23 JP JP2016561079A patent/JP6563950B2/ja active Active
- 2014-12-23 EA EA201691126A patent/EA033227B1/ru active Protection Beyond IP Right Term
- 2014-12-23 MX MX2016008594A patent/MX368835B/es active IP Right Grant
- 2014-12-23 EP EP19175726.9A patent/EP3566694A1/fr active Pending
- 2014-12-23 EP EP18171127.6A patent/EP3384898A1/fr active Pending
- 2014-12-23 DK DK14825154.9T patent/DK3089735T3/en active
- 2014-12-23 LT LTEP14825154.9T patent/LT3089735T/lt unknown
- 2014-12-23 HU HUE14825154A patent/HUE039513T2/hu unknown
- 2014-12-23 PL PL14825154T patent/PL3089735T3/pl unknown
- 2014-12-23 KR KR1020167020695A patent/KR101861117B1/ko active Active
- 2014-12-23 PT PT14825154T patent/PT3089735T/pt unknown
- 2014-12-23 MY MYPI2016001207A patent/MY182861A/en unknown
- 2014-12-23 WO PCT/EP2014/079259 patent/WO2015101576A1/fr not_active Ceased
- 2014-12-23 ES ES14825154.9T patent/ES2687345T3/es active Active
- 2014-12-23 GE GEAP201814191A patent/GEP20186855B/en unknown
- 2014-12-23 AU AU2014375301A patent/AU2014375301C1/en active Active
- 2014-12-23 UA UAA201606910A patent/UA117845C2/uk unknown
- 2014-12-23 SI SI201430881T patent/SI3089735T1/sl unknown
- 2014-12-23 EP EP14825154.9A patent/EP3089735B1/fr active Active
- 2014-12-23 CN CN202010180583.6A patent/CN111150728B/zh active Active
- 2014-12-23 CN CN201480071526.7A patent/CN105848641B/zh active Active
- 2014-12-23 PE PE2016000968A patent/PE20160997A1/es unknown
- 2014-12-23 KR KR1020187007444A patent/KR101861119B1/ko active Active
- 2014-12-23 SG SG11201605311UA patent/SG11201605311UA/en unknown
- 2014-12-23 HR HRP20181551TT patent/HRP20181551T1/hr unknown
- 2014-12-29 TW TW103146043A patent/TWI660747B/zh active
- 2014-12-29 AR ARP140104938A patent/AR098982A1/es not_active Application Discontinuation
- 2014-12-30 US US14/585,533 patent/US10596113B2/en active Active
-
2016
- 2016-06-28 SA SA516371427A patent/SA516371427B1/ar unknown
- 2016-06-28 MA MA39155A patent/MA39155A1/fr unknown
- 2016-06-28 PH PH12016501268A patent/PH12016501268B1/en unknown
- 2016-06-28 CL CL2016001653A patent/CL2016001653A1/es unknown
- 2016-06-28 IL IL246498A patent/IL246498B/en active IP Right Grant
- 2016-06-29 US US15/196,318 patent/US10617638B2/en active Active
-
2018
- 2018-09-11 CY CY181100949T patent/CY1120668T1/el unknown
-
2019
- 2019-07-25 JP JP2019136785A patent/JP6823118B2/ja active Active
-
2023
- 2023-08-17 AR ARP230102185A patent/AR130239A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA39154A1 (fr) | Composition stable pressurisée de solution pour aérosol d'une combinaison de bromure de glycopyrronium et de formotérol | |
| EA201691126A1 (ru) | Находящаяся под давлением стабильная аэрозольная композиция комбинации гликопиррония бромида и формотерола в форме раствора | |
| AR081540A1 (es) | Proceso para proveer particulas con cargas electroestaticas reducidas | |
| RU2012142295A (ru) | Способ приготовления частиц носителя для сухих порошков для ингаляции | |
| HRP20140864T1 (hr) | Kombinacije koje sadrže antimuskarinska sredstva i beta-adrenergiäśke agoniste | |
| PE20160155A1 (es) | Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos | |
| JP2016510012A5 (fr) | ||
| RU2018103940A (ru) | Фармацевтические композиции, содержащие антагонист интегрина альфа4, для применения в лечении воспалительных состояний глаза | |
| BR112022012361A2 (pt) | Inaladores pressurizados de dose calibrada compreendendo uma formulação farmacêutica tamponada | |
| HK1215388A1 (zh) | 可吸入药用组合物和含有该药用组合物的吸入器装置 | |
| US20230277451A1 (en) | A pharmaceutical formulation for pressurised metered dose inhaler | |
| JP2014527056A5 (fr) | ||
| CO6270213A2 (es) | Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion | |
| JP2011500731A5 (fr) | ||
| CO7310521A2 (es) | Composición farmaceútica que tiene fluidez mejorada, agente medicional, y método para la producción y uso del mismo | |
| TH171992A (th) | องค์ประกอบสารละลายชนิดละอองลอยแบบอัดความดันที่เสถียรของการรวมกันของ ไกลโคไพร์โรเนียมโบรไมด์ และฟอร์โมเทอรอล | |
| ZA202108150B (en) | An inhalable fixed dose powder composition comprising glycopyrronium, formoterol and fluticasone propionate | |
| TH171993A (th) | องค์ประกอบสารละลายชนิดละอองลอยแบบอัดความดันที่เสถียรของการรวมกันของ ไกลโคไพร์โรเนียมโบรไมด์ และฟอร์โมเทอรอล | |
| PL432374A1 (pl) | Nowy inhalacyjny system terapeutyczny dostarczający zredukowaną ilość propionianu flutikazonu i salmeterolu o zwiększonej skuteczności i profilu bezpieczeństwa | |
| NZ786610A (en) | Stainless steel can for pressurised metered dose inhalers | |
| TR201716233A2 (tr) | Solunum yolları hastalıklarının tedavisi için birden fazla etken madde içeren farmasötik bileşim. | |
| TR201714893A1 (tr) | Beta-2 Agonisti ve Kortikosteroid içeren kuru toz bileşimi. | |
| TH147031A (th) | ขนาดการให้ยาและสูตรผสมชนิดใหม่ | |
| UA109530C2 (uk) | Композиції, способи та системи для доставки респіраторним шляхом двох чи більше активних агентів |